{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977929",
  "id": "02977929",
  "pages": 17,
  "price_sensitive": false,
  "date": "20250807",
  "time": "1014",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250807/pdf/06mmnhnchrl4y2.pdf",
  "summary": "### Summary of Material Information (OncoSil Medical ASX Announcement \u2013 Investor Webinar Presentation):\n\n#### **Commercial & Operational Highlights:**  \n- **Record OncoSil\u2122 dose sales in Q4 FY25** \u2013 Signals commercial traction.  \n- **Geographic expansion**: Targeting new regions (US, Gulf, Egypt, Nordic) with existing approvals in 30+ countries (EU, UK, Turkey, Israel).  \n- **Label expansions**:  \n  - **PANCOSIL study** (percutaneous delivery) \u2013 100% recruitment completed; target commercial availability Q4 CY25.  \n  - **TRIPP-FFX study** (FOLFIRINOX chemo combo) \u2013 100% recruitment completed; regulatory submission target Q3/Q4 CY25.  \n- **Manufacturing**: Sydney facility to produce first commercial doses in Q4 CY25 (gross margin target: 65% in CY26, >75% at scale).  \n- **German reimbursement**: Conditional approval for 120 hospitals under G-BA trial; tender shortlisted for second round.  \n\n#### **Clinical & Regulatory Catalysts:**  \n- **Comparative data**: OncoSil + chemo showed **20.0 months OS** vs. 12.3 months for chemo alone, **28.6% resection rate** (vs. 12.1%).  \n- **TGA submission** completed Q2 CY25; approval anticipated Q4 CY25.  \n- **US pathway**: Constructive FDA discussions for bile duct cancer (dCCA) under HDE; IDE filing for pancreatic cancer (LAPC) expected H1 CY26.  \n\n#### **Capital Raising:**  \n- **$8.7M raised** (before costs) via:  \n  - $6.7M institutional placement.  \n  - $2.0M SPP (oversubscribed by $2.4M).  \n\n#### **Upcoming Milestones (next 12\u201318 months):**  \n- Q4 CY25: PANCOSIL label expansion, TGA approval, Sydney facility production.  \n- H1 CY26: G-BA trial commencement, US IDE filing, Gulf region launch.  \n\n**Omitted**: Background details, leadership bios, non-material market statistics.  \n\n**Material Impact**: Expansion catalysts, revenue growth potential from new markets/delivery methods, and margin improvements.",
  "usage": {
    "prompt_tokens": 6911,
    "completion_tokens": 485,
    "total_tokens": 7396,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-07T02:00:17.976494"
}